This is the version of the explanation I wish somebody had given me, written down before I forget what confused me. It is about alcohol, and it is deliberately narrow — everything I am not confident about is marked as such.
What is actually established
Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience pathway that quiets food noise. The practical part people get wrong is that tolerance changes: less food in the stomach, faster gastric emptying of liquid relative to solids, and a smaller body mean the same two drinks land considerably harder than they used to.
The condition it depends on
If the change has opened a harder question about someone's drinking, that belongs with a service rather than a thread.
What I am not sure about
What I actually want to know is whether the change in tolerance is the smaller stomach, the smaller body, or something central, and whether it settles. Tell me what I have not thought of.
sarah_nash92 said:Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience…
Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.
sarah_nash92 said:Reduced interest in alcohol is one of the most consistently reported off-target effects, and the mechanism is plausibly the same reward-salience…
I read this differently. The confidence in this thread is running ahead of the evidence, and I would rather the uncertainty were stated than smoothed over because it is unsatisfying.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsTaking the question as asked, rather than the general version of it. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.
Correct me if the detail matters more than I have assumed.
RetaRick_CA said:Agreed, and ALT falling is not the same as fibrosis improving.
Mine went the same way, slower. I had assumed I was the exception until I read this.